Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Off-Label Ruling Opens Window For Shift In FDA Regulation, PhRMA Says

Executive Summary

PhRMA would like FDA to focus on the quality of off-label communication rather than the intent; one attorney says the Caronia decision may result in reduced government settlements and another warns of reading the ruling too favorably for industry.


Related Content

Off-label Ruling’s Potential Fallout Is “Terrifying,” FDA’s Temple Says
Pfizer Settles Protonix Off-Label Allegations – Pricing Investigation Still Unresolved
Off-Label Enforcement, Not Promotion, May See First Changes After Free Speech Ruling


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts